Lyon - HCL
Welcome,         Profile    Billing    Logout  
 4 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MARTIN, Etienne
SPORADIC, NCT06656598: Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
BladderSpar, NCT03697850 / 2018-001807-35: Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

Active, not recruiting
2
79
Europe
Atezolizumab
UNICANCER, Roche Pharma AG
Bladder Cancer
06/25
02/29
i-RTCT, NCT03117946: Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy

Recruiting
N/A
220
Europe
Biological samples
Centre Hospitalier Universitaire de Besancon
Lung Cancer, Head and Neck Cancer
08/26
11/26
ADERE, NCT06668038: Contribution of Multicenter Expertise and Deformable Fusion Software for Re-irradiations With Curative Intent

Not yet recruiting
N/A
100
Europe
Multidisciplinary and multicenter validation of re-irradiation with curative intent
Centre Leon Berard
Re-irradiation, Radiotherapy
02/27
02/29
RADIO-RYTHMIC, NCT04731610: Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma

Recruiting
N/A
314
Europe
Radiotherapy, Surveillance after resection
Institut Curie
Thymoma Malignant Recurrent
12/28
12/29
STEREO-OS, NCT03143322: Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

Active, not recruiting
N/A
168
Europe
SBRT
UNICANCER, National Cancer Institute, France
Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Bone Metastases
07/25
07/27
Bladder-ART, NCT03333356: Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

Active, not recruiting
N/A
81
Europe
pelvic radiotherapy
UNICANCER
Patients With High-risk MIBC
12/27
12/27
PRIMALung, NCT04790253: PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients ( Study)

Recruiting
N/A
600
Europe
Prophylactic cranial irradiation
European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER
Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
04/28
04/28
SWALDUZ, Aurélie
COMET, NCT06908993: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Not yet recruiting
3
133
Europe
Tepotinib, Pemetrexed (Alimta), Vinorelbine, Gemcitabine alone, Docetaxel, Paclitaxel, Pembrolizumab, Nivolumab, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
03/28
07/28
TARLANEC, NCT06937905: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Not yet recruiting
3
129
Europe
Standard of Care Chemotherapy, Tarlatamab
Intergroupe Francophone de Cancerologie Thoracique
Neuroendocrine Carcinoma
09/28
03/30
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Active, not recruiting
3
349
Europe
Pembrolizumab, Pembrolizumab and Chemotherapy drugs
University Hospital, Brest, Groupe Français de Pneumo-Cancérologie
Non-small-cell Lung Cancer
12/25
12/25
CODEBREAK-IGR, NCT05631249 / 2021-006958-31: Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Recruiting
2
40
Europe
Sotorasib 120Mg Tab
Gustave Roussy, Cancer Campus, Grand Paris, AMGEN
KRAS P.G12C, Non Small Cell Lung Cancer
12/27
12/27
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Recruiting
2
100
Europe
Durvalumab
UNICANCER, AstraZeneca
Small Cell Lung Carcinoma
02/28
02/30
AMPHISARC, NCT05180695: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Recruiting
1/2
58
Europe
Pazopanib, Votrient, HDM201, siremadlin
Centre Leon Berard, Novartis, National Cancer Institute, France
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
01/26
07/26
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours

Recruiting
1
25
Europe
DO-2
DeuterOncology
Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer
12/25
12/26
ERICA, NCT04676009: Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients

Completed
N/A
26
Europe
Exercise arm :
Centre Leon Berard, Claude Bernard University, Lyon Cancer Research Centre, Hospices Civils de Lyon, Inter-university Laboratory of Human Movement Biology
Carcinoma, Non-Small-Cell Lung
12/23
01/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MARTIN, Etienne
SPORADIC, NCT06656598: Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Not yet recruiting
2
152
Europe
Carboplatin, Paclitaxel, Cemiplimab, Curative hypofractionated radiotherapy, Cemiplimab (maintenance)
Intergroupe Francophone de Cancerologie Thoracique
Stage III NSCLC
09/28
01/32
BladderSpar, NCT03697850 / 2018-001807-35: Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

Active, not recruiting
2
79
Europe
Atezolizumab
UNICANCER, Roche Pharma AG
Bladder Cancer
06/25
02/29
i-RTCT, NCT03117946: Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy

Recruiting
N/A
220
Europe
Biological samples
Centre Hospitalier Universitaire de Besancon
Lung Cancer, Head and Neck Cancer
08/26
11/26
ADERE, NCT06668038: Contribution of Multicenter Expertise and Deformable Fusion Software for Re-irradiations With Curative Intent

Not yet recruiting
N/A
100
Europe
Multidisciplinary and multicenter validation of re-irradiation with curative intent
Centre Leon Berard
Re-irradiation, Radiotherapy
02/27
02/29
RADIO-RYTHMIC, NCT04731610: Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma

Recruiting
N/A
314
Europe
Radiotherapy, Surveillance after resection
Institut Curie
Thymoma Malignant Recurrent
12/28
12/29
STEREO-OS, NCT03143322: Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

Active, not recruiting
N/A
168
Europe
SBRT
UNICANCER, National Cancer Institute, France
Metastatic Breast Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Bone Metastases
07/25
07/27
Bladder-ART, NCT03333356: Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

Active, not recruiting
N/A
81
Europe
pelvic radiotherapy
UNICANCER
Patients With High-risk MIBC
12/27
12/27
PRIMALung, NCT04790253: PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients ( Study)

Recruiting
N/A
600
Europe
Prophylactic cranial irradiation
European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER
Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
04/28
04/28
SWALDUZ, Aurélie
COMET, NCT06908993: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Not yet recruiting
3
133
Europe
Tepotinib, Pemetrexed (Alimta), Vinorelbine, Gemcitabine alone, Docetaxel, Paclitaxel, Pembrolizumab, Nivolumab, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
03/28
07/28
TARLANEC, NCT06937905: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Not yet recruiting
3
129
Europe
Standard of Care Chemotherapy, Tarlatamab
Intergroupe Francophone de Cancerologie Thoracique
Neuroendocrine Carcinoma
09/28
03/30
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %

Active, not recruiting
3
349
Europe
Pembrolizumab, Pembrolizumab and Chemotherapy drugs
University Hospital, Brest, Groupe Français de Pneumo-Cancérologie
Non-small-cell Lung Cancer
12/25
12/25
CODEBREAK-IGR, NCT05631249 / 2021-006958-31: Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Recruiting
2
40
Europe
Sotorasib 120Mg Tab
Gustave Roussy, Cancer Campus, Grand Paris, AMGEN
KRAS P.G12C, Non Small Cell Lung Cancer
12/27
12/27
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
DURVALUNG, NCT05617963 / 2021-005920-39: Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Recruiting
2
100
Europe
Durvalumab
UNICANCER, AstraZeneca
Small Cell Lung Carcinoma
02/28
02/30
AMPHISARC, NCT05180695: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Recruiting
1/2
58
Europe
Pazopanib, Votrient, HDM201, siremadlin
Centre Leon Berard, Novartis, National Cancer Institute, France
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
01/26
07/26
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours

Recruiting
1
25
Europe
DO-2
DeuterOncology
Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer
12/25
12/26
ERICA, NCT04676009: Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients

Completed
N/A
26
Europe
Exercise arm :
Centre Leon Berard, Claude Bernard University, Lyon Cancer Research Centre, Hospices Civils de Lyon, Inter-university Laboratory of Human Movement Biology
Carcinoma, Non-Small-Cell Lung
12/23
01/24

Download Options